ministrative 4,552 2,683
Total operating expenses 14,705 11,523
Loss from operations (2,832) (520)
Interest and other income 603 586
Income (loss) before income taxes (2,229) 66
Provision for income taxes (8) (7)
Net income (loss) $(2,237) $59
Net income (loss) per share - basic &
diluted $(0.09) $0.00
Weighted average shares outstanding
used in calculating net income
(loss) per common share:
Basic 23,630,842 22,978,331
Diluted 23,630,842 24,792,543
Thermage, Inc.
NON-GAAP RECONCILIATION OF OPERATING INCOME (LOSS), NET INCOME (LOSS) AND
NET INCOME (LOSS) PER SHARE
(in thousands, except share and per share data)
(unaudited)
Three Months Ended
March 31,
2008 2007
GAAP loss from operations $(2,832) $(520)
Non-GAAP adjustments to loss from operations:
Stock-based compensation (c) 979 1,261
Non-GAAP income (loss) from operations $(1,853) $741
GAAP net income (loss) $(2,237) $59
Non-GAAP adjustments to net income (loss):
Stock-based compensation (c) 979 1,261
Non-GAAP net income (loss)
'/>"/>
SOURCE Thermage, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 Related biology technology :1.
Thermage, Inc. to Present at the 10th Annual Needham & Company Growth Conference2.
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients3.
YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 264.
Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering5.
BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.6.
Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets7.
China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results8.
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain9.
Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter10.
ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer11.
Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line